Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent deficiency or absence of sexual desire. It can cause prominent distress and interpersonal difficulty of women. There have been drugs available to treat sexual disorders in men when there is no such drug for women. Nowadays, FDA approved Flibanserin to treat HSDD of premenopausal women. This drug Flibanserin has no novel mechanism of action but the possible mechanism of action is modulating serotonin and dopamine activity in brain parts as balance of these systems is significance for a normal sexual response. Keywords: Hypoactive Sexual Desire Disorder, Premenopausal women, FlibanserinÂ
Flibanserin acts at cortical, limbic, hypothalamic, and brainstem nuclei to inhibit serotonin releas...
Background: Female sexual dysfunction (FSD) affects as many as 1 in every 3 women, with a significan...
ABSTRACT: Introduction: Flibanserin treatment increases sexual desire and satisfying sexual events ...
Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent deficiency or absence of sexua...
Female sexual disorders are increasingly being recognized in the population and hypoactive sexual de...
Christopher J Jayne,1 Michael J Heard,2 Sarah Zubair,3 Dustie L Johnson4 1Greater Houston Urogyn, 2...
Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affe...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 100mg Flibanser...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Flibanserin is ...
Nicole M Lodise Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Al...
Low sexual desire is the most common sexual complaint in women. As a result, many women suffer from ...
In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as a treatment for hy...
BACKGROUND: The efficacy of flibanserin in treating hypoactive sexual desire disorder (HSDD) is base...
The objective of the International Society for the Study of Women\u27s Sexual Health expert consensu...
Introduction: Hypoactive sexual desire disorder (HSDD) often has a negative impact on the health and...
Flibanserin acts at cortical, limbic, hypothalamic, and brainstem nuclei to inhibit serotonin releas...
Background: Female sexual dysfunction (FSD) affects as many as 1 in every 3 women, with a significan...
ABSTRACT: Introduction: Flibanserin treatment increases sexual desire and satisfying sexual events ...
Hypoactive sexual desire disorder (HSDD) is a persistent or recurrent deficiency or absence of sexua...
Female sexual disorders are increasingly being recognized in the population and hypoactive sexual de...
Christopher J Jayne,1 Michael J Heard,2 Sarah Zubair,3 Dustie L Johnson4 1Greater Houston Urogyn, 2...
Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affe...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 100mg Flibanser...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Flibanserin is ...
Nicole M Lodise Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Al...
Low sexual desire is the most common sexual complaint in women. As a result, many women suffer from ...
In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as a treatment for hy...
BACKGROUND: The efficacy of flibanserin in treating hypoactive sexual desire disorder (HSDD) is base...
The objective of the International Society for the Study of Women\u27s Sexual Health expert consensu...
Introduction: Hypoactive sexual desire disorder (HSDD) often has a negative impact on the health and...
Flibanserin acts at cortical, limbic, hypothalamic, and brainstem nuclei to inhibit serotonin releas...
Background: Female sexual dysfunction (FSD) affects as many as 1 in every 3 women, with a significan...
ABSTRACT: Introduction: Flibanserin treatment increases sexual desire and satisfying sexual events ...